Older white males with advanced bladder cancer more likely to commit suicide
the ONA take:
Older white males with advanced bladder cancer are the most likely to commit suicide among patients with genitourinary cancers, according to a recent study published in Cancer.
Zachary Klaassen, MD, of the Medical College of Georgia at Georgia Regents University and fellow researchers looked through the NCI’s SEER database from 1988 to 2010 and identified 1.2 million patients with cancer of the prostate, bladder, kidney, testes, and penis. They examined variables such as age, sex, race, as well as the aggressiveness of both the disease and treatment.
Their findings stressed suicide as a matter of public concern that requires physician awareness among men with genitourinary cancers. In particular, patients who were older, male and have more aggressive disease were found to be the most likely to commit suicide.
“The older, white, single male is already at higher risk in the general society for suicide,” Dr. Klaassen said. “Add on the fact that he has advanced bladder cancer and this is a high-risk patient. But this has taught me that we have to look for warning signs in all these patients.”
Older white males with advanced bladder cancer are the most likely to commit suicide among patients with genitourinary cancers.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|